Daniela Elena Matei

Grants

Grants per year 2013 2025

• 13 Finished
• 15 Active

Grants per year

Search results

• Active

  Prot #mRNA-2416-P101: A Phase I/II, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone and in Combination with Durvalumab for Patients wit

  Matei, D. E.

  PPD Investigator Services, LLC, ModernaTX, Inc

  11/11/20 → 11/11/23

  Project: Research project

• The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS)

  Barber, E. L., Davuluri, R. V., Kim, J. J., Lee, J., Matei, D. E., Simon, M. A., Wei, J. & Strohl, A. E.

  National Cancer Institute

  9/17/20 → 8/31/23

  Project: Research project

  • neoplasms
  • translational medical research
  • research programs
  • infrastructure
  • planning

• Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer for The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS)

  Matei, D. E.

  National Cancer Institute

  9/17/20 → 8/31/23

  Project: Research project

• IPA Agreements FY20 - Wang

  Matei, D. E.

  Jesse Brown VA Medical Center

  10/1/19 → 9/30/21

  Project: Research project

• IPA Agreement FY20 - Zhang

  Matei, D. E.

  Jesse Brown VA Medical Center

  10/1/19 → 9/30/21

  Project: Research project

  • students

• Prot #AL3818-US-004: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

  Matei, D. E.

  Advenchen Laboratories, LLC

  9/20/19 → 9/20/22

  Project: Research project

• Targeting Ovarian Cancer Stem Cells Interactions with the Niche

  Matei, D. E.

  Indiana University, U.S. Army Medical Research and Materiel Command

  8/1/19 → 7/31/23

  Project: Research project

• Northwestern University Lead Academic Participating Site

  Matei, D. E. & Benson III, A. B.

  National Cancer Institute

  4/1/19 → 2/28/25

  Project: Research project

  • Clinical Trials
  • performance

• The Robert H. Lurie Comprehensive Cancer Center

  Agulnik, M., Awatramani, R., Cella, D., Chakravarti, D., Chandel, N., Crispino, J. D., Cristofanilli, M., Eklund, E. A., Frankfurt, O., Horbinski, C. M., Horvath, C. M., Hussain, M., James, C. D., Kelleher, N. L., Khan, S. A., LaBonne, C., Larson, A. C., Matei, D. E., Mrksich, M., Munshi, H. G., Murphy, A. B., Penedo, F. J., Perlman, H. R., Peter, M. E., Rademaker, A. W., Rappoport, J. Z., Scheidt, K. A., Simon, M. A., Sosman, J. A., Spring, B., Wei, J., Weiss, E. L., Woloschak, G. E., Obeng, R., Hitsman, B. L., Butt, Z., Arvanitis, C., Wignall, S., Shilatifard, A., Kocherginsky, M., Rini, C., Bonini, M., Kumthekar, P. U., Mondragon, A., Benson III, A. B., Gordon, L. I., Green, K. J., Rosenzweig, A. C., Meade, T. J., Platanias, L. C., Carthew, R. W., Backman, V. & Hahn, E. A.

  National Cancer Institute

  8/10/18 → 7/31/23

  Project: Research project

  • neoplasms
  • medicine

• Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells

  Chakravarti, D., Condello, S., Matei, D. E., Shahabi, S. & Wei, J.

  National Cancer Institute

  8/1/18 → 7/31/23

  Project: Research project

  • Neoplastic Stem Cells
  • Ovarian Neoplasms
  • Lipids
  • Heterografts
  • Raman Spectrum Analysis

• Diversity Supplement for Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells

  Matei, D. E.

  National Cancer Institute

  8/1/18 → 7/31/23

  Project: Research project

• Prot #C-700-01: A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to

  Matei, D. E.

  Agenus Inc.

  9/29/17 → 9/29/23

  Project: Research project

• Prot #BTCRC GYN15-013: Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

  Matei, D. E.

  Hoosier Cancer Research Network, Inc., Merck Sharp & Dohme Corporation

  8/17/17 → 8/17/23

  Project: Research project

• Prot #NU 16G03: An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

  Matei, D. E.

  Merck Sharp & Dohme Corporation

  10/18/16 → 10/18/22

  Project: Research project

• Prot #NU12G11: The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  Matei, D. E., Pineda, M. J. & Scholtens, D. M.

  National Comprehensive Cancer Network, AVEO Pharmaceuticals, Inc.

  5/6/13 → 10/31/21

  Project: Research project